Related references
Note: Only part of the references are listed.The discovery and development of rivaroxaban
Frank Misselwitz et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALIST CANDIDATES OF THE PRIX GALIEN USA, INTERNATIONAL, AND PRO BONO HUMANITARIAN AWARDS 2010 (2011)
Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?
Emmanuel J. Favaloro et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study
A. Tripodi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
New oral antithrombotics: a need for laboratory monitoring. For
P. Mismetti et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
New oral antithrombotics: a need for laboratory monitoring. Against
H. Bounameaux et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
New oral anticoagulants in development
Jeffrey I. Weitz
THROMBOSIS AND HAEMOSTASIS (2010)
Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
Yu Chen Barrett et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
BI Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
BAY 59-7939:: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement.: A phase II dose-ranging study
AGG Turpie et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939):: An oral, direct factor Xa inhibitor
S Roehrig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation
DL McGlasson et al.
BLOOD COAGULATION & FIBRINOLYSIS (2005)
Share Paper
